Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8012MR)

This product GTTS-WQ8012MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8012MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4971MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ15270MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ12187MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ7131MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ15760MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ6399MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ10939MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ11720MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MILR1444A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW